4MT2001

4MT2001 is a novel, orally administered small molecule that acts as a potent and selective inhibitor of glycogen synthase kinase 3 beta (GSK3β). It is the primary metabolite of ruboxistaurin, originally developed by Eli Lilly. Unlike ruboxistaurin, 4MT2001 demonstrates improved GSK3β potency and selectivity, superior pharmacokinetic and pharmacodynamic properties, and supports once-daily dosing. Preclinical studies show that 4MT2001 achieves central nervous system target engagement at low doses with significant reductions in biomarkers associated with GSK3β activity (such as pCRMP2), paralleling positive behavioral effects in animal models. The drug has shown a favorable safety profile in GLP toxicology studies without cardiovascular adverse effects at high exposures. Its development is focused on neuropsychiatric and neurodegenerative diseases—primarily bipolar disorder (as a mood stabilizer) and agitation in Alzheimer’s disease—with additional exploration for SYNGAP1-related disorders due to its mechanism enhancing synaptic plasticity and neurogenesis[1][2][3][5][8].